Evidence map›Paper›PMID 37575259›Full record

ArticleFrontiers in immunology2023

NFκB1 inhibits memory formation and supports effector function of ILC2s in memory-driven asthma.

Mukesh Verma, Divya Verma, Anand Santosh Sripada, Kapil Sirohi, Rangati Varma, Anita Sahu, Rafeul Alam

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. PGI2 restricts trained ILC2 responses in allergic inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2025
    Article
  5. Article
  6. Review
  7. Update on type 2 immunity.The Journal of allergy and clinical immunology · 2025
    Review
  8. The Role of Nuclear Factor-κB in Cancer Immunity and Immunoediting.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mukesh VermaDivision of Allergy & Immunology, Department of Medicine, National Jewish Health, Denver, CO, United States.
Divya VermaDivision of Allergy & Immunology, Department of Medicine, National Jewish Health, Denver, CO, United States.
Anand Santosh SripadaDivision of Allergy & Immunology, Department of Medicine, National Jewish Health, Denver, CO, United States.
Kapil SirohiDivision of Allergy & Immunology, Department of Medicine, National Jewish Health, Denver, CO, United States.
Rangati VarmaDivision of Allergy & Immunology, Department of Medicine, National Jewish Health, Denver, CO, United States.
Anita SahuDivision of Allergy & Immunology, Department of Medicine, National Jewish Health, Denver, CO, United States.
Rafeul AlamDivision of Allergy & Immunology, Department of Medicine, National Jewish Health, Denver, CO, United States.
University of Colorado Denver · USNational Jewish Health · US

Funding

ILC2 memory in asthmaR01AI157138 · NIAID · NATIONAL JEWISH HEALTH · PI ALAM, RAFEUL · 2020 to 2024
$3.1M
DNA induction of neutrophilic asthmaR01AI165922 · NIAID · NATIONAL JEWISH HEALTH · PI ALAM, RAFEUL · 2021 to 2025
$2.5M
NIAID NIH HHS R01 AI157138NIAID NIH HHS R01 AI165922
6 · The paper itself

Abstract

Background: ILC2s are capable of generating memory. The mechanism of memory induction and memory-driven effector function (trained immunity) in ILC2s is unknown. Objective: NFκB1 is preferentially expressed at a high level in ILC2s. We examined the role of NFkB1 in memory induction and memory-driven effector function in a mouse model of asthma. Methods: Intranasal administration of Alternaria, flexivent, ELISA, histology, real-time PCR, western blot, flow cytometry and immunofluorescence staining. Results: NFκB1 was essential for the effector phase of memory-driven asthma. NFκB1 was critical for IL33 production, ILC2 generation, and production of type-2 cytokines, which resulted in eosinophilic inflammation and other features of asthma. NFκB1 induction of type-2 cytokines in ILC2s was independent of GATA3. NFκB1 was important for allergen induction of ILC3s and FoxP3+ Tregs. NFκB1 did not affect Th2 cells or their cytokine production. In contrast to its protagonistic role in the effector phase, NFκB1 had an antagonistic role in the memory phase. NFκB1 inhibited allergen-induced upregulation of memory-associated repressor and preparedness genes in ILC2s. NFκB1 upregulated RUNX1. NFκB1 formed a heterodimer with RUNX1 in ILC2s. Conclusions: NFκB1 positively regulated the effector phase but inhibited the induction phase of memory. The foregoing pointed to an interdependent antagonism between the memory induction and the memory effector processes. The NFκB1-RUNX1 heterodimer represented a non-canonical transcriptional activator of type-2 cytokines in ILC2s.

Indexed as

AsthmaImmunity, InnateAllergensAnimalsCore Binding Factor Alpha 2 SubunitCytokinesLymphocytesMiceNF-kappa B p50 SubunitAllergensCore Binding Factor Alpha 2 SubunitCytokinesNF-kappa B p50 SubunitasthmaIL2sIL33memoryNFκB1RUNX1

Identifiers

PMID37575259
PMCPMC10415221
OpenAlexW4385326257

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.